Rituximab and omalizumab in severe, refractory insulin allergy.
Yong
Patrick F K
PF
Malik
Rifat
R
Arif
Sefina
S
Peakman
Mark
M
Amiel
Stephanie
S
Ibrahim
Mohammad A A
MA
Gough
Andrew
A
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007155:Immunologic Factors / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects*; D008875:Middle Aged; D000069444:Omalizumab; D000069283:Rituximab
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007328:Insulin; D000069444:Omalizumab; D007073:Immunoglobulin E; D000069283:Rituximab